AzTrials
AzTrials

ColonoscopyPhase 3B-CLEANRNCT02976805

Multi-centre Failed Bowel Prep RCT

A Phase 3 study testing 4L PegLyte + 15 mg bisacodyl and 6L PegLyte + 15 mg bisacodyl in people with Colonoscopy and Bowel Preparation, run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's at 4 sites in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a multi-centre randomized clinical trial comparing the efficacy of two different bowel preparation regimens for patients who have already failed a bowel preparation for colonoscopy. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Colonoscopy, Bowel Preparation
What is being tested?
4L PegLyte + 15 mg bisacodyl and 6L PegLyte + 15 mg bisacodyl
Could I receive a placebo?
No, everyone receives an active treatment
How many people
196 participants
Where
4 sitesCanada
Study dates
13 Feb 2017to 19 Feb 2020
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Anyone undergoing a repeat colonoscopy due to failed bowel preparation at index colonoscopy. Failure is defined as preparation quality inadequate to detect lesions > 5 mm after washing and requiring a shortened colonoscopy interval as a result.
  • Age > 18 years
  • Outpatient colonoscopy
  • Indication for full colonoscopy

Who cannot join

  • Subject refusal
  • Able to comprehend the trial
  • Index colonoscopy performed as an inpatient
  • Pregnancy or breastfeeding
  • Allergies to the employed bowel preparations
  • Any colonic surgery
Show all 18Show fewer
  • History of ischemic colitis
  • Congestive heart failure
  • Chronic renal failure
  • Cirrhosis
  • Severe electrolyte imbalance
  • Non-adherence to index bowel preparation defined as failure to follow diet instructions and/or consume the entire volume of bowel preparation medication as prescribed for any reason (ex. eating a normal diet on the day of colonoscopy, PEG intolerance, etc…)
  • Use of bowel preparation in an off-label manner for the index colonoscopy.
  • Inability to follow verbal and written instructions in English or French.
  • Ileus, gastric outlet obstruction, gastrointestinal obstruction, bowel preforation
  • Toxic coitis or toxic megacolon
  • Acute surgical abdomen including appendicitis
  • Gastroenteritis and acute diverticulitis

Trial locations and contacts

4 sites in 1 country.

Canada4 sites
  • University of Alberta Hospital

    Edmonton, Alberta

  • London Health Sciences Centre

    London, Ontario

  • CHUM

    Montreal, Quebec

  • McGill University Health Centre

    Montreal, Quebec

Other trials in Canada

About this study

Official title: A Multi-centre Endoscopist Blinded Randomized Clinical Trial to Compare Two Bowel Preparations After a Colonoscopy With Inadequate Bowel Preparation

This is a multi-centre randomized clinical trial comparing the efficacy of two different bowel preparation regimens for patients who have already failed a bowel preparation for colonoscopy.

Read the detailed description

PURPOSE

The purpose of this multi-centre randomized clinical trial is to compare two bowel preparation regimens for patients who fail to cleanse their colon during their index colonoscopy. Although many clinical trials already exist examining the optimal bowel preparation for colonoscopy in general, surprisingly none address patients who failed bowel preparation in the past. Failure to achieve bowel preparation is a result of complex factors, including underlying colonic dysmotility, co-morbidities, and concurrent medication usage and is rarely the result of patient non-compliance.(1) Given the frequency of inadequate bowel preparation, its negative impact on colonoscopy quality, the increased risk for an adverse event, and the need to repeat the procedure, an important public health need exists to address this question urgently.(1) This study will use many of the same methodology and investigators as an ongoing Canadian multicenter study titled, "The Bowel CLEAnsing: a National initiative ( B-CLEAN) " but on a smaller scale to answer this question.

BACKGROUND

Adequate bowel preparation is a prerequisite for high quality colonoscopy and is needed to maximize visualization of the colonic mucosa.(1-4) Unfortunately, inadequate bowel preparation is common and reported to occur in 4% to 17% of cases.(5-12) Procedures with poor preparation are more likely to be incomplete, have an adverse event, and are less likely to detect polyps.(1, 9, 13) Repeat colonoscopies within one year have shown a 36% miss rate for advanced adenomas in these patients.(12) Recognizing the importance of high quality colonoscopy, Cancer Care Ontario and other provincial health authorities now track adequacy rates for bowel preparation.

In cases of poor bowel preparation, the colonoscopy must be repeated, exposing patients to another invasive procedure and adding additional costs to the healthcare system. Although health economic data regarding colonoscopy utilization in Canada is sparse, an illustrative example from the United States is possible. Assuming 14.2 million screening colonoscopies are performed annually in the United States (14) of which 5% have inadequate bowel preparation (6, 8), a total of 710,000 colonoscopies have to be repeated at a cost of $763 million dollars, based on a per case cost of $1,075.(15) This is likely an underestimation of the true cost due to exclusion of non-screening colonoscopies in the calculation and the use of a low colonoscopy cost estimate based on the Nationwide Colonoscopy Program for the Uninsured.(15)

There are numerous definitions of inadequate bowel preparation and the term's lack of specificity contributes to the varied incidence of inadequate bowel preparation reported in the literature. The Boston Bowel Preparation Scale (BBPS) is a user friendly validated measure that is based on three colonic segment scores (right, transverse, left, each scored between 0 - 3) and is summed for a total score between 0 - 9.(16, 17)(Appendix A) Adequacy was recently formally defined in a large study involving 2,516 patients undergoing colonoscopies at 36 centres as a total score ≥6 and/or all segment scores ≥2.(18)

The optimal bowel preparation to use for repeat colonoscopy in patients who failed the initial preparation is unknown. However, a combination of a stimulant, such as bisacodyl, and a larger volume of an electrolyte and fluid balanced osmotic laxative, such as PEG, is often used. In a recent case series, Ibanez et al.(19) identified 83 patients with inadequate bowel preparation at their index colonoscopy. 51 patients agreed to a repeat colonoscopy using an 'intensive' regimen consisting of a low fibre diet, bisacodyl, and 3L split dose polyethylene glycol (PEG). Using this regimen, 90% had adequate bowel preparation at the second colonoscopy. However, the bowel preparation at the index colonoscopy was not given in a split dose manner in the majority of patients, which is now the standard of practice due to superior cleansing, and the lack of a control group makes an accurate assessment of efficacy impossible.(1) In another study, patients with inadequate bowel preparation after split dose PEG (4L) were offered a repeat colonoscopy the same day after ingestion of another 2L of PEG or a colonoscopy 1 week later using a low fibre diet, bisacodyl, and 4L split dose PEG.(20) There was no difference in adequacy of bowel preparation although 20% of cases were still inadequate and the lack of randomization and blinding threaten the validity of these results.

To date, no consensus exists regarding the optimal bowel preparation regimen to use in patients with inadequate cleansing due to the absence of clinical trials. Given 4% to 17% of colonoscopies have inadequate bowel preparation, there is a significant public health need to address this issue.(5-12, 21-23) A highly efficacious yet tolerable bowel preparation regimen is needed for these patients to ensure adequate cleansing for their next procedure. The objective of this multi-centre randomized clinical trial will be to compare the efficacy of two regimens in achieving adequate bowel preparation after failing to cleanse at the index colonoscopy.

PROJECT DESCRIPTION

3.1 Study Design, Randomization, and Blinding This multi-centre randomized clinical trial will compare two bowel preparation regimens for patients who have already failed bowel preparation at their index colonoscopy, defined as inadequate visualization to detect lesions > 5 mm and requiring a shortened colonoscopy interval as a result. This clinical definition of failed bowel preparation was chosen instead of the BBPS since the latter may not be available from the index colonoscopy depending on the endoscopist. However, where possible, the BBPS at the index colonoscopy will be recorded. A total of four centres from the original B-CLEAN study group have agreed to participate (Appendix E).

Subjects will be randomized to one of 2 arms (see '3.2 Selection of Bowel Preparation Regimens' for details). Randomization will be performed centrally using Research Electronic Data Capture (REDCap) in a 1:1 allocation in blocks of varying sizes stratified by site. In addition, data entry will be performed online through REDCap.

Blinding of the endoscopist will be strictly enforced. Endoscopists are required to remain blinded to the subject's bowel preparation until after completing the bowel cleanliness section of the CRF. Subjects will be asked to not discuss the bowel preparation with any endoscopy unit staff except for research personnel until the colonoscopy preparation rating has been completed by the endoscopist. Unfortunately, blinding of the patient (ie. double blinding) is impossible due to the volume differences between the two bowel preparation regimens.

3.2 Selection of Bowel Preparation Regimens Regimen A: 4L PegLyte + 15 mg bisacodyl Regimen B: 6L PegLyte + 15 mg bisacodyl

There is no standard bowel preparation utilized after a colonoscopy with failed bowel preparation. Regimen A was adapted from Ibanez et al.(19) who used a regimen consisting of 3L polyethylene glycol (PEG) and 10 mg bisacodyl with reasonable effectiveness. In our study, 4L PEG is used instead of 3L to avoid reducing the amount of PEG consumed by those who were originally prepped with 4L PegLyte at their index colonoscopy. 15 mg bisacodyl was used instead of 10 mg for consistency with dosing used in BiPegLyte. This regimen is modestly more intensive than standard bowel preparation due to an additional 2L PEG compared to BiPegLyte and 15 mg bisacodyl compared to 4L PegLyte.

Regimen B was adapted from Kim et al.(20) as a more intensive yet tolerable regimen. In this regimen, 6L of PEG is combined with 15 mg of bisacodyl.

3.3 Bowel Preparation \& Colonoscopy Subjects will be randomized in a 1:1 allocation to either regimen A or B. Regardless of randomization, subjects will be instructed to follow a low fibre diet for 2 days followed by clear fluid diet for 24 hours prior to the scheduled colonoscopy. The time and amount of PEG the subjects will consume will depend on randomization.(APPENDIX B) To optimize patient adherence, all participants will receive a handout with their specific bowel preparation instructions based on their randomization.

All colonoscopies will be performed within 12 weeks of randomization but not within 2 weeks of index colonoscopy (ie. washout period from the index bowel preparation). Procedures will be performed according to local standard operating procedures. All participating endoscopists will complete standardized training and calibration in the use of the Boston Bowel Preparation Scale prior to the start of the study at http://www.bmc.org/gastroenterology/research.htm. A record of training will be sent to the coordinating centre.

For subjects who do not present for their colonoscopy after randomization (ie. forgot appointment), they may remain in the study and be prepped with the same regimen again as long as their next colonoscopy is not scheduled within the next two weeks. For subjects who decline ongoing study participation, they can withdraw and follow up with their physician.

3.4 Baseline Data Collection

  1. Age
  2. Gender
  3. Weight
  4. Height
  5. Primary Language
  6. Highest level of education
  7. Patient's ability to understand and follow the bowel preparation directives at home as deemed by the research personnel (Y/N)
  8. Charlson co-morbidity index score (24)
  9. Irritable bowel syndrome according to ROME III criteria (25) 8. Functional constipation according to ROME III criteria (25) 9. Neurologic disorders: Parkinson's disease, multiple sclerosis, cerebral palsy, other 10. Previous abdominal/pelvic surgery 11. Established diagnosis of inflammatory bowel disease. 12. Medication usage 13. Information regarding index colonoscopy
  10. Method of communication for index colonoscopy
  11. Bowel preparation used
  12. Use of split dose bowel preparation (Y/N)
  13. Did patient followed the diet as prescribed (Y/N)
  14. Did patient take bowel preparation medication as prescribed (Y/N)
  15. Subject willingness to repeat the index bowel preparation
  16. Subject incontinence \& travel time with index bowel preparation 14. Indication for index colonoscopy (screening, surveillance, diagnostic)

3.5 Statistical Considerations Sample size was calculated as follows. Assuming 70% adequacy among those randomized to regimen A, 87.5% adequacy among those randomized to regimen B, significance of 0.05, and power of 0.8, 85 patients are required in each group (total = 170). An adequacy rate of 70% was selected based on the existing literature.(19, 20) Additional factors considered in arriving at this figure include the lack of split dosing used at the index colonoscopy (19), inadequate intake of PEG at the index colonoscopy (20), and the performance of the second colonoscopy within a week of the first.(20) An adequacy rate of 87.5% was selected based on a 25% relative increase in adequacy to be considered clinically significant. Based on a target sample size of 170 and a conservative 15% dropout, 196 subjects are required for the study.

Descriptive statistics will be reported as mean (SD), median (range), and proportions as appropriate. Data will be analyzed as intention-to-treat and hypothesis testing performed with t-test, chi-square, and Fisher's exact test as appropriate. Pre-planned secondary analyses will include per-protocol analysis, stratification by timing of colonoscopy (ie. morning versus afternoon procedures), and stratification by initial bowel preparation used.

Being tested
4L PegLyte + 15 mg bisacodyl, 6L PegLyte + 15 mg bisacodyl

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 4L PegLyte + 15 mg bisacodylDrug

    Also called Regimen A

    Randomized

  • 6L PegLyte + 15 mg bisacodylDrug

    Also called Regimen B

    Randomized

Study groups in NCT02976805
Study groupRoleWhat they receive
Regimen AExperimental4L PegLyte + 15 mg bisacodyl
Receives: Drug: 4L PegLyte + 15 mg bisacodyl
Regimen BExperimental6L PegLyte + 15 mg bisacodyl
Receives: Drug: 6L PegLyte + 15 mg bisacodyl

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Adequate bowel preparation

    BBPS total score ≥6 and/or all segment scores ≥2.

    Measured: Once after colonoscopy

Secondary outcomes (5)
  1. Mean BBPS total score

    Measured: Once after colonoscopy

  2. Bowel preparation was adequate after washing to visualize lesions > 5 mm of importance to the procedure and there is no need to shorten the interval of the next colonoscopy

    Measured: Once after colonoscopy

  3. Validated patient tolerability questionnaire for bowel preparation score

    Measured: Once after colonoscopy

  4. Bowel preparation related adverse event

    The following moderate and non-lasting symptoms related to bowel prep are expected and not considered adverse events:

    • Nausea
    • Vomiting
    • Abdominal fullness
    • Bloating
    • Abdominal cramps and pain
    • Diarrhea
    • Anal irritation

    Otherwise, all AEs will be classified as follows:

    Severity:

    • Mild
    • Moderate
    • Severe

    Causality:

    • Unrelated
    • Possible
    • Probable
    • Highly probable

    Outcome:

    • Resolved without residual effects
    • Resolved with residual effects
    • Recovering/Resolving
    • Not Recovered/Not Resolved
    • Death
    • Unknown

    A Serious Adverse Event (SAE) is defined as an event that

    • Led to a death
    • Led to a serious deterioration in the health of the subject that resulted in a life-threatening illness or injury, permanent impairment of a body structure or function, hospitalization or prolongation of hospitalization, or required medical or surgical intervention to prevent permanent impairment of a body structure or function

    Measured: After colonoscopy and 14 days after colonoscopy

  5. Right sided BBPS sub-score

    Measured: Up to 4 weeks after colonoscopy

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Nov 2016 (estimated)
  2. Study start13 Feb 2017
  3. Primary completion19 Feb 2020
  4. Study completion19 Feb 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Investigator
Enrolment
196 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02976805
Sponsor's protocol ID
HSREB108472
Acronym
B-CLEANR
Status last verified
Jan 2020
First submitted
25 Nov 2016
Last updated
21 Feb 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • ASGE Standards of Practice Committee; Saltzman JR, Cash BD, Pasha SF, Early DS, Muthusamy VR, Khashab MA, Chathadi KV, Fanelli RD, Chandrasekhara V, Lightdale JR, Fonkalsrud L, Shergill AK, Hwang JH, Decker GA, Jue TL, Sharaf R, Fisher DA, Evans JA, Foley K, Shaukat A, Eloubeidi MA, Faulx AL, Wang A, Acosta RD. Bowel preparation before colonoscopy. Gastrointest Endosc. 2015 Apr;81(4):781-94. doi: 10.1016/j.gie.2014.09.048. Epub 2015 Jan 14. No abstract available.

    PubMed 25595062
  • Rex DK. Optimal bowel preparation--a practical guide for clinicians. Nat Rev Gastroenterol Hepatol. 2014 Jul;11(7):419-25. doi: 10.1038/nrgastro.2014.35. Epub 2014 Apr 1.

    PubMed 24686267
  • Hassan C, Bretthauer M, Kaminski MF, Polkowski M, Rembacken B, Saunders B, Benamouzig R, Holme O, Green S, Kuiper T, Marmo R, Omar M, Petruzziello L, Spada C, Zullo A, Dumonceau JM; European Society of Gastrointestinal Endoscopy. Bowel preparation for colonoscopy: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy. 2013;45(2):142-50. doi: 10.1055/s-0032-1326186. Epub 2013 Jan 18.

    PubMed 23335011
  • Johnson DA, Barkun AN, Cohen LB, Dominitz JA, Kaltenbach T, Martel M, Robertson DJ, Boland CR, Giardello FM, Lieberman DA, Levin TR, Rex DK. Optimizing adequacy of bowel cleansing for colonoscopy: recommendations from the U.S. multi-society task force on colorectal cancer. Gastrointest Endosc. 2014 Oct;80(4):543-562. doi: 10.1016/j.gie.2014.08.002. No abstract available.

    PubMed 25220509
  • Yee R, Manoharan S, Hall C, Hayashi A. Optimizing bowel preparation for colonoscopy: what are the predictors of an inadequate preparation? Am J Surg. 2015 May;209(5):787-92; discussion 792. doi: 10.1016/j.amjsurg.2014.12.018. Epub 2015 Feb 12.

    PubMed 25796095
  • MacPhail ME, Hardacker KA, Tiwari A, Vemulapalli KC, Rex DK. Intraprocedural cleansing work during colonoscopy and achievable rates of adequate preparation in an open-access endoscopy unit. Gastrointest Endosc. 2015 Mar;81(3):525-30. doi: 10.1016/j.gie.2014.05.002. Epub 2014 Jul 3.

    PubMed 24998464
  • Dik VK, Moons LM, Huyuk M, van der Schaar P, de Vos Tot Nederveen Cappel WH, Ter Borg PC, Meijssen MA, Ouwendijk RJ, Le Fevre DM, Stouten M, van der Galien O, Hiemstra TJ, Monkelbaan JF, van Oijen MG, Siersema PD; Colonoscopy Quality Initiative. Predicting inadequate bowel preparation for colonoscopy in participants receiving split-dose bowel preparation: development and validation of a prediction score. Gastrointest Endosc. 2015 Mar;81(3):665-72. doi: 10.1016/j.gie.2014.09.066. Epub 2015 Jan 17.

    PubMed 25600879
  • Ben-Horin S, Bar-Meir S, Avidan B. The outcome of a second preparation for colonoscopy after preparation failure in the first procedure. Gastrointest Endosc. 2009 Mar;69(3 Pt 2):626-30. doi: 10.1016/j.gie.2008.08.027.

    PubMed 19251002
  • Froehlich F, Wietlisbach V, Gonvers JJ, Burnand B, Vader JP. Impact of colonic cleansing on quality and diagnostic yield of colonoscopy: the European Panel of Appropriateness of Gastrointestinal Endoscopy European multicenter study. Gastrointest Endosc. 2005 Mar;61(3):378-84. doi: 10.1016/s0016-5107(04)02776-2.

    PubMed 15758907
  • Ness RM, Manam R, Hoen H, Chalasani N. Predictors of inadequate bowel preparation for colonoscopy. Am J Gastroenterol. 2001 Jun;96(6):1797-802. doi: 10.1111/j.1572-0241.2001.03874.x.

    PubMed 11419832
  • Hookey LC, Vanner SJ. Pico-salax plus two-day bisacodyl is superior to pico-salax alone or oral sodium phosphate for colon cleansing before colonoscopy. Am J Gastroenterol. 2009 Mar;104(3):703-9. doi: 10.1038/ajg.2008.167. Epub 2009 Feb 17.

    PubMed 19223885
  • Lebwohl B, Kastrinos F, Glick M, Rosenbaum AJ, Wang T, Neugut AI. The impact of suboptimal bowel preparation on adenoma miss rates and the factors associated with early repeat colonoscopy. Gastrointest Endosc. 2011 Jun;73(6):1207-14. doi: 10.1016/j.gie.2011.01.051. Epub 2011 Apr 8.

    PubMed 21481857
  • Clark BT, Rustagi T, Laine L. What level of bowel prep quality requires early repeat colonoscopy: systematic review and meta-analysis of the impact of preparation quality on adenoma detection rate. Am J Gastroenterol. 2014 Nov;109(11):1714-23; quiz 1724. doi: 10.1038/ajg.2014.232. Epub 2014 Aug 19.

    PubMed 25135006
  • Seeff LC, Richards TB, Shapiro JA, Nadel MR, Manninen DL, Given LS, Dong FB, Winges LD, McKenna MT. How many endoscopies are performed for colorectal cancer screening? Results from CDC's survey of endoscopic capacity. Gastroenterology. 2004 Dec;127(6):1670-7. doi: 10.1053/j.gastro.2004.09.051.

    PubMed 15578503
  • Nationwide Colonoscopy Program for the Uninsured [cited 2015 September 21]. Available from: http://www.colonoscopyassist.com/After_Colonoscopy.html.

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing 4L PegLyte + 15 mg bisacodyl and 6L PegLyte + 15 mg bisacodyl in people with Colonoscopy and Bowel Preparation, run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's at 4 sites in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Feb 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Adequate bowel preparation (time frame: Once after colonoscopy). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02976805, which also lists 29 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Feb 2020.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in